Myalgia during interferon therapy--does it warrant monitoring muscle enzymes?
John
Anil
A
Department of Gastroenterology, Medical Research Centre, Hamad Medical Corporation, Doha, Qatar. aniljohn44@gmail.com
John
Anjum S
AS
Al
Kaabi Saad
KS
Singh
Rajvir
R
Derbala
Moutaz
M
Yakoub
Rafie
R
D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects*; D015415:Biomarkers / Q000097:blood; D003402:Creatine Kinase / Q000097:blood*; D016903:Drug Monitoring; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D007770:L-Lactate Dehydrogenase / Q000097:blood*; D008297:Male; D009220:Myositis / Q000139:chemically induced / Q000517:prevention & control*; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011446:Prospective Studies; D011994:Recombinant Proteins
D000998:Antiviral Agents; D015415:Biomarkers; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D007770:L-Lactate Dehydrogenase; D003402:Creatine Kinase; C100416:peginterferon alfa-2a